3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide
C24H24N6O — CID 118240434
Data last refreshed: (MolForge compound catalog, from PubChem)
About 3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide
3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide (PubChem CID 118240434) has the molecular formula C24H24N6O and a molecular weight of 412.50 g/mol. Its IUPAC name is 3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide.
Molecular Properties
| Compound Name | 3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide |
|---|---|
| PubChem CID | 118240434 |
| Molecular Formula | C24H24N6O |
| Molecular Weight | 412.50 g/mol |
| Exact Mass | 412.20 |
| IUPAC Name | 3-[4-(benzylamino)-5-methyl-6,7-dihydropyrrolo[3,2-d]pyrimidin-2-yl]-2-methylindolizine-8-carboxamide |
| SMILES | Cc1cc2c(C(N)=O)cccn2c1-c1nc2c(c(NCc3ccccc3)n1)N(C)CC2 |
| InChI | InChI=1S/C24H24N6O/c1-15-13-19-17(22(25)31)9-6-11-30(19)20(15)24-27-18-10-12-29(2)21(18)23(28-24)26-14-16-7-4-3-5-8-16/h3-9,11,13H,10,12,14H2,1-2H3,(H2,25,31)(H,26,27,28) |
| InChIKey | AWBJXNOMDKREBU-UHFFFAOYSA-N |
| XLogP | 3.41 |
| TPSA | 88.55 Ų |
| H-Bond Donors | 2 |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 5 |
| Heavy Atoms | 31 |
| Complexity | — |
Lipinski Rule of Five
Passes Rule of Five
| Rule | Value |
|---|---|
| MW ≤ 500 | 412.50 |
| LogP ≤ 5 | 3.41 |
| H-Bond Donors ≤ 5 | 2 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 118240434 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.